retinopathy semaglutide Ozempic: is a GLP-1 receptor agonist used for type 2 diabetes and cardiovascular risk reduction in selected patients, commonly causing nausea, vomiting, diarrhea, constipation, abdominal pain, reduced appetite, and weight loss New study finds semaglutide may

Clinicians should specifically inquire about the nature, timing, and associated features of fatigue

Physiol Behav (1994) 56(2):2379

High BBB complaint volumes relative to the company size and age are concerning

GPF received lecture fees or grant support from Abbott, AstraZeneca, Boehringer, Lilly, Merck-Sharp-Dome, Mundipharma, Novartis, Novo Nordisk, Sanofi, Servier

Schedule your free consultation today and discover how simple transformative weight loss can be

Key Takeaways Section 13 Pass-through PBMs remove rebate retention and spread pricing from the PBM revenue model, replacing them with transparent PMPM administrative fees, but hold less than 10% combined market share as of 2025